"A week of weakness

Last but not least (barely) is MannKind (Nasdaq: MNKD ) . Shares fell over 15% for the week. As was the case with Threshold, there weren’t any new announcements that caused the stock to decline.

Actually, MannKind reported a little bit of good news this week. The company wrapped up the patient recruiting process for phase 3 trials for Afrezza, its long-awaited insulin inhalant. Mr. Market yawned, and simply watched as shares continued their three-week skid.

The last great hope for MannKind is to find a good partner with plenty of cash. More horrendous weeks could be in store until it does. On the other hand, with a share price only a little above $2, there’s a lot more room to move up than down at this point."

http://healthcaye.com/tag/until-it-does/